Back to Search
Start Over
Efficacy of Vaginally Administered Gel Containing Emtricitabine and Tenofovir Against Repeated Rectal Simian Human Immunodeficiency Virus Exposures in Macaques.
- Source :
-
Journal of Infectious Diseases . 10/15/2018, Vol. 218 Issue 8, p1284-1290. 7p. - Publication Year :
- 2018
-
Abstract
- Vaginal microbicides containing antiretrovirals (ARVs) have shown to prevent vaginally acquired human immunodeficiency virus (HIV), but these products may not protect women who engage in anal sex. Intravaginal dosing with ARVs has shown to result in drug exposures in rectal tissues, thus raising the possibility of dual compartment protection. To test this concept, we investigated whether intravaginal dosing with emtricitabine (FTC)/tenofovir (TFV) gel, which fully protected macaques against repeated vaginal exposures to simian human immunodeficiency virus (SHIV), protects against rectal SHIV exposures. Pharmacokinetic studies revealed rapid distribution of FTC and TFV to rectal tissues and luminal fluids, albeit at concentrations 1-2 log10 lower than those in the vaginal compartment. Efficacy measurements against repeated rectal SHIV challenges demonstrated a 4.5-fold reduction in risk of infection in macaques that received intravaginal FTC/TFV compared to placebo gel (P = .047; log-rank test). These data support the concept of dual compartment protection by vaginal dosing and warrants developing ARV-based vaginal products with improved bidirectional dosing. [ABSTRACT FROM AUTHOR]
- Subjects :
- *ANTIRETROVIRAL agents
*TENOFOVIR
*HIV infections
*ANAL sex
*MACAQUES
Subjects
Details
- Language :
- English
- ISSN :
- 00221899
- Volume :
- 218
- Issue :
- 8
- Database :
- Academic Search Index
- Journal :
- Journal of Infectious Diseases
- Publication Type :
- Academic Journal
- Accession number :
- 131699520
- Full Text :
- https://doi.org/10.1093/infdis/jiy301